

# PEPFAR Perspectives on Xpert RIF/MTB



William Coggin, OGAC Heather Alexander, CDC Amy Piatek, USAID


GLI Partners Meeting Annecy, April 19, 2012



## **A Unified Response**

#### **PEPFAR Commitment to TB/HIV**

- PEPFAR is leading a unified U.S. Government response to global TB/HIV
- PEPFAR supports national TB and HIV/AIDS programs that fully integrate TB/HIV services
- PEPFAR funding for TB/HIV programs has increased more than 800% over five years





#### Framework for PEPFAR TB/HIV Programming

#### WHO-recommended collaborative TB/HIV activities

- A. Establish and strengthen the mechanisms for delivering integrated TB and HIV services
- A.1. Set up and strengthen a coordinating body for collaborative TB/HIV activities functional at all levels
- A.2. Determine HIV prevalence among TB patients and TB prevalence among people living with HIV
- A.3. Carry out joint TB/HIV planning to integrate the delivery of TB and HIV services
- A.4. Monitor and evaluate collaborative TB/HIV activities

B. Reduce the burden of TB in people living with HIV and initiate early antiretroviral therapy (the *Three I's for HIV/TB*)

B.1. Intensify TB case-finding and ensure high quality antituberculosis treatment

- B.2. Initiate TB prevention with Isoniazid preventive therapy and early antiretroviral therapy
- B.3. Ensure control of TB Infection in health-care facilities and congregate settings

C. Reduce the burden of HIV in patients with presumptive and diagnosed TB

- C.1. Provide HIV testing and counselling to patients with presumptive and diagnosed TB
- C.2. Provide HIV prevention interventions for patients with presumptive and diagnosed TB
- C.3. Provide co-trimoxazole preventive therapy for TB patients living with HIV

C.4. Ensure HIV prevention interventions, treatment and care for TB patients living with HIV

C.5. Provide antiretroviral therapy for TB patients living with HIV

WHO policy on collaborative TB/HIV activities Guidelines for nationa programmes and other stakeholders

WHO Policy on Collaborative TB/HIV Activities, 2012



# **TB/HIV as part of AIDS Free Generation**

#### Emphasis areas:

- HIV testing, beyond TB cases: TB patients' family members/contacts, TB suspects;
- Early ART for all HIV-infected TB patients;
- Ramping up of ART in TB clinics.
- TB screening and diagnosis in ANC and PMTCT settings, effective linkages to care and treatment
- PHDP (positive health, dignity and prevention).




# PEPFAR Support for Laboratory Integration and Strengthening Systems


l																
Laboratory Systems	Quality Management System															
	Training & Retention Systems	C	E												tems	
	Equipment Maintenance Systems & Biosafety	P	E												ning ih Sys oility	
	Supply Chain Management Systems	E	E												V ngthe / Healt itainat	
	Laboratory Information & Data Management Systems	C	F			ł						F	1		V Strei oratory Sus	
	Sample Referral Systems													K		
	Institutions & Policies														·	
			serology	Molecular Testing	<b>D</b>	Hematology		Chemistry		CD4		Culture	Microscopv			
			Ser									Cu	Micro			
					Labo	orat	ory	Tec	hno	logi	es					




# **National Laboratory Strategic Plans**







- 283 labs
- 22 countries





# **Results**

#### □ In FY 2011, PEPFAR-supported programs:

- Screened more than 3.8 million PLWH for TB in HIV care or treatment settings
- Started TB treatment for 230,800 patients enrolled in HIV care or treatment programs
- Support for more that over 13,500 facilities providing care and treatment services for PLWH in high TB prevalence settings
- Supported 4,884 facilities (laboratories) with capacity to perform clinical laboratory tests



# **USG Support for Xpert MTB/RIF**

"...USAID, PEPFAR, and the U.S. Centers for Disease Control and Prevention (CDC), are committed to working together to support the rapid scale-up and appropriate use of this new technology."

Amb E Goosby, Admin. R Shah, Director T Frieden









### Resources <sup>1,2</sup>

• As of December 2011 (136):

- Machines procured: 54
- Machines planned: 82
- Cartridges: ??

#### 2010/11 supplemental funding

- Planned (\$11M):
  - Machines: 100
  - Cartridges: 300,000 (3000 per machine, year 1)

uation

#### 2012 Country Operational Plans: TBD

- 1. Cartridge volume projected at current \$16.86 price
- 2. Includes PEPFAR-supported projects implemented via CDC and USAID

# Programmatic Xpert MTB/RIF Roll-Out: USG Approach

- Coordinated CDC, USAID, and OGAC approach
  - Close WHO collaboration
- Comprehensive package of support and technical assistance
  - Led by Ministry of Health
  - Assessment of priorities, gaps, and stakeholders
  - Development of an implementation and quality assurance plan
  - Preparation of testing sites and procurement of machines/tests
  - Training of laboratory and clinical staff
  - Supervision, monitoring and evaluation

 Emphasis on systems strengthening to address entire diagnostic cascade.

# Programmatic Xpert MTB/RIF Roll-Out: USG Tools for Field Staff

- Phased Implementation and Evaluation of Xpert MTB/RIF: Principal considerations for USG-funded activities (available)
- Technical framework for Xpert MTB/RIF roll-out (draft)
- Guide to Xpert MTB/RIF introduction, validation, and quality assurance (draft/pilot)

Laboratory and programmatic M&E indicators (draft/pilot)

# Kenya ICF PHE and Diagnostics Study - 1



### DGHA, DTBE, KEMRI/CDC, and NTLP collaboration

#### Objectives

- To evaluate the performance of various diagnostic tests among HIV-infected persons in Kenya
- To determine the performance of 3 clinical screening methods for ruling out TB in HIV-infected persons
- To determine the prevalence and incidence of TB among HIV-infected persons

# Kenya ICF PHE and Diagnostics Study - 2

#### Laboratory Strengthening

- Specimen collection and transport
- Microscopy center infrastructure
- KEMRI-CDC Kisian TB laboratory strengthening toward accreditation
- Biosafety
- New diagnostic implementation
- Result recording and reporting







# **Botswana XPRES Study - 1**

### **DGHA, DTBE, BOTUSA, and MOH collaboration**

### Objectives

- To compare sensitivity of Xpert-based TB diagnostic algorithm to pre-Xpert smear microscopy-based TB diagnostic algorithm among TB suspects
- To evaluate the impact of the "Xpert package" on TB incidence during the first 6 months of ART



# Botswana XPRES Study - 2

#### Laboratory Strengthening

- Specimen referral and result reporting systems
- Testing site infrastructure
- Biosafety
- New diagnostic implementation
- Xpert MTB/RIF external quality assessment (EQA) program






# Namibia 3 l's Scale-Up - 1

DGHA, DTBE, OGAC, USAID, and MOH collaboration

#### Objective

 To integrate TB/HIV collaborative activities into existing facility and community based TB and HIV programs using best practices and evidence-based approaches while leveraging advancements in TB diagnostics.





# Namibia 3 l's Scale-Up - 2



#### Laboratory Strengthening

- National TB Laboratory Strategic Plan
- Specimen referral and result reporting systems
- TB Reference Laboratory strengthening toward accreditation
- Biosafety
- New diagnostic implementation
- Laboratory information system
- LED smear microscopy external quality assessment (EQA) program
- Xpert MTB/RIF EQA program



# **Priorities for discussion**

#### How can funders and technical agencies:

- Coordinate to hasten volume price reduction of cartridges?
- Better share information and coordinated programming?
- Effectively promote roll-out TA and EQA?
- Effectively contribute to knowledge base?
- Strengthen MOH leadership?
- Further sustainability and assured ongoing funding for cartridges?
- Further support GLI coordination?





For more information, please visit: <u>www.PEPFAR.gov</u> <u>www.facebook.com/PEPFAR</u> <u>http://twitter.com/USPEPFAR</u>

